Rheumatoid ArthritisPhase 3OSKIRA - 2NCT01197534
Evaluation of Effectiveness of Two Dosing Regimens of Fostamatinib Compared to Placebo in Patients With Rheumatoid Arthritis (RA) Who Are Taking Disease Modifying Anti-rheumatic Drug (DMARD) But Not Responding.
A Phase 3 study testing fostamatinib in people with Rheumatoid Arthritis, run by AstraZeneca at 149 sites in 16 countries.
Trial summary
The purpose of the study is to evaluate the effectiveness of two dosing regimens of fostamatinib compared to placebo, in patients with rheumatoid arthritis (RA) who are taking disease modifying anti-rheumatic drug (DMARD) but not responding. The study will last for 1 year. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Rheumatoid Arthritis
- What is being tested?
- fostamatinib
- Type of treatment
- Pill or oral medicine
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 913 participants
- Where
- 149 sitesin 16 countries
- Study dates
- Sep 2010to Mar 2013
- Phase
- Phase 3
- Are there results?
- Yes, posted in the registrySummary in the doctors' view
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Active rheumatoid arthritis (RA) diagnosed after the age of 16
- Treatment with one the following disease modifying anti-rheumatic drug: methotrexate, sulfasalazine, hydroxychloroquine or chloroquine
- 4 or more swollen joints and 4 or more tender/painful joints (from 28 joint count)and either Erythrocyte Sedimentation Rate (ESR) blood result of 28mm/h or more, or C-Reactive Protein (CRP) blood result of 10mg/L or more
- At least one of the following: documented history of positive rheumatoid factor (blood test), current presence of rheumatoid factor (blood test), radiographic erosion within 12 months prior to study enrolment, presence of serum anti-cyclic citrullinated peptide antibodies (blood test)
Who cannot join
- Females who are pregnant or breast feeding
- Poorly controlled hypertension
- Liver disease or significant liver function test abnormalities
- Certain inflammatory conditions (other than rheumatoid arthritis), connective tissue diseases or chronic pain disorders
- Recent or significant cardiovascular disease
- Significant active or recent infection including tuberculosis
Show all 9Show fewer
- Previous failure to respond to a TNF alpha antagonist, anakinra or previous treatment with other biological agent
- Severe renal impairment
- Neutropenia
Trial locations and contacts
149 sites in 16 countries.
149 sites in 16 countries
United States57 sites
Research Site
Amarillo, Texas
Research Site
Austin, Texas
Research Site
Birmingham, Alabama
Research Site
Boca Raton, Florida
Research Site
Boise, Idaho
Research Site
Brandon, Florida
Research Site
Brooklyn, New York
Research Site
Canton, Georgia
Research Site
Charlotte, North Carolina
Research Site
Chesapeake, Virginia
Research Site
Crofton, Maryland
Research Site
Cumberland, Maryland
Research Site
Dallas, Texas
Research Site
Dayton, Ohio
Research Site
Decatur, Georgia
Research Site
Duncansville, Pennsylvania
Research Site
Durham, North Carolina
Research Site
Elizabethtown, Kentucky
Research Site
Flowood, Mississippi
Research Site
Glendale, Arizona
Research Site
Greenville, South Carolina
Research Site
Hagerstown, Maryland
Research Site
Hot Springs, Arkansas
Research Site
Houston, Texas
Research Site
Huntington Beach, California
Research Site
Jacksonville, Florida
Research Site
Kalamazoo, Michigan
Research Site
Kalispell, Montana
Research Site
Las Cruces, New Mexico
Research Site
Lubbock, Texas
Research Site
Macon, Georgia
Research Site
Manalapan, New Jersey
Research Site
Memphis, Tennessee
Research Site
Mesa, Arizona
Research Site
Mesquite, Texas
Research Site
Miami, Florida
Research Site
Omaha, Nebraska
Research Site
Orangeburg, South Carolina
Research Site
Orlando, Florida
Research Site
Philadelphia, Pennsylvania
Research Site
Phoenix, Arizona
Research Site
Rochester, New York
Research Site
Roslyn, New York
Research Site
San Antonio, Texas
Research Site
Scottsdale, Arizona
Research Site
South Bend, Indiana
Research Site
St Louis, Missouri
Research Site
Syracuse, New York
Research Site
Tacoma, Washington
Research Site
Tampa, Florida
Research Site
Torrance, California
Research Site
Trumbull, Connecticut
Research Site
Tucson, Arizona
Research Site
Venice, Florida
Research Site
Washington D.C., District of Columbia
Research Site
West Reading, Pennsylvania
Research Site
Zephyrhills, Florida
Canada11 sites
Research Site
Bowmanville, Ontario
Research Site
Edmonton, Alberta
Research Site
Hamilton, Ontario
Research Site
Mississauga, Ontario
Research Site
Montreal, Quebec
Research Site
Ottawa, Ontario
Research Site
Québec, Quebec
Research Site
Reading
Research Site
Toronto, Ontario
Research Site
Trois-Rivières, Quebec
Research Site
Winnipeg, Manitoba
Czechia11 sites
Research Site
Brno
Research Site
Bruntál
Research Site
Česká Lípa
Research Site
České Budějovice
Research Site
Hlučín
Research Site
Liberec
Research Site
Ostrava - Trebovice
Research Site
Prague
Research Site
Sokolov
Research Site
Terezín
Research Site
Zlín
India11 sites
Research Site
Ahmedabad, Gujarat
Research Site
Bangalore, Karnataka
Research Site
Coimbatore, Tamil Nadu
Research Site
Gandhinagar, Gujarat
Research Site
Hyderabad, Andhra Pradesh
Research Site
Lucknow
Research Site
Madurai, Tamil Nadu
Research Site
Mangalore, Karnataka
Research Site
Mumbai, Maharashtra
Research Site
Pune, Maharashtra
Research Site
Vadodara, Gujarat
United Kingdom9 sites
Research Site
Basingstoke
Research Site
Cambridge
Research Site
Eastbourne, Sussex
Research Site
London
Research Site
Maidstone, Kent
Research Site
Newcastle upon Tyne
Research Site
Solihull, West Midlands
Research Site
Stoke-on-Trent
Research Site
Swindon
Israel8 sites
Research Site
Ashkelon
Research Site
Beer Yaakov
Research Site
Haifa
Research Site
Kfar Saba
Research Site
Petah Tikva
Research Site
Ramat Gan
Research Site
Rehovot
Research Site
Tel Aviv
Ukraine8 sites
Research Site
Kharkiv
Research Site
Kyiv
Research Site
Lutsk
Research Site
Lviv
Research Site
Simferopol
Research Site
Vinnytsia
Research Site
Zaporizhzhya
Research Site
Zaporyzhzhya
South Africa6 sites
Research Site
Cape Town, W Cape
Research Site
Durban, Kz-natal
Research Site
Kempron Park, Gauteng
Research Site
Port Elizabeth
Research Site
Pretoria, Gauteng
Research Site
Stellenbosch
Italy4 sites
Research Site
Iesi, AN
Research Site
Legnano, MI
Research Site
Udine, UD
Research Site
Varese, VA
Romania4 sites
Research Site
Baia Mare
Research Site
Brailari
Research Site
Bucharest
Research Site
Ploieşti
Serbia4 sites
Research Site
Belgrade
Research Site
Kragujevac
Research Site
Niška Banja
Research Site
Novi Sad
Spain4 sites
Research Site
Barcelona
Research Site
Getafe
Research Site
La Laguna (tenerife), Canary Islands
Research Site
Mérida, Extremadura
Germany3 sites
Research Site
Erlangen
Research Site
Hamburg
Research Site
München
Lithuania3 sites
Research Site
Kaunas
Research Site
Klaipėda
Research Site
Šiauliai
About this study
Official title: (OSKIRA-2): A Phase III, Multi-centre, Randomised, Double-Blind, Placebo-Controlled, Parallel Group Study of Two Dosing Regimens of Fostamatinib Disodium in Rheumatoid Arthritis Patients With an Inadequate Response to DMARDs
The purpose of the study is to evaluate the effectiveness of two dosing regimens of fostamatinib compared to placebo, in patients with rheumatoid arthritis (RA) who are taking disease modifying anti-rheumatic drug (DMARD) but not responding. The study will last for 1 year.
Read the detailed description
Sub-study:
Full title: Optional Genetic Research
Date: 18 June 2010
Version: 1
Objectives: To collect and store, with appropriate consent ,DNA samples for future exploratory research into genes/genetic variation that may influence response (ie, absorption, distribution, metabolism and excretion, safety, tolerability and efficacy) to fostamatinib disodium and/or methotrexate; and/or susceptibility to, progression of and prognosis of RA
- Conditions
- Rheumatoid Arthritis
- Being tested
- fostamatinib, placebo, fostamatinib
- Keywords
- Rheumatoid Arthritis
- Medical subject headings
- Arthritis, Rheumatoid
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
fostamatinibDrug
fostamatinib 100 mg twice daily
fostamatinibDrug
fostamatinib 100 mg twice daily/ 150 mg once daily
placebo, fostamatinibDrug
Placebo for 24 weeks followed by fostamatinib 100 mg twice daily.
| Study group | Role | What they receive |
|---|---|---|
| Dosing Regimen A | Experimental | Oral Treatment Receives: Drug: fostamatinib |
| Dosing Regimen B | Experimental | Oral Treatment Receives: Drug: fostamatinib |
| Dosing Regimen C | Placebo comparator | Oral Treatment Receives: Drug: placebo, fostamatinib |
What is being measured
The primary outcome is the main question the study is designed to answer.
Proportion of Patients With ACR20 at Week 24, Comparison Between Fostamatinib and Placebo
ACR20: American College of Rheumatology 20% response criteria, based on count of swollen and tender joints (out of 28 joints), blood test measures of inflammation (such as CRP) and the physician and patient's own assessments of disease activity, pain and physical function. BID = twice daily, CRP = C-reactive protein, DMARD = disease-modifying anti-rheumatic drug, PO = orally, QD = once a day.
Measured: 24 weeks
Secondary outcomes (11)
Proportion of Patients Achieving ACR20, Comparison Between Fostamatinib and Placebo at Week 1
ACR20: American College of Rheumatology 20% response criteria, based on count of swollen and tender joints (out of 28 joints), blood test measures of inflammation (such as CRP) and the physician and patient's own assessments of disease activity, pain and physical function. BID = twice daily, CRP = C-reactive protein, DMARD = Disease-modifying anti-rheumatic drug, PO = orally, QD = once a day.
Measured: 1 week
Proportion of Patients Achieving ACR50, Comparison Between Fostamatinib and Placebo at Week 24
ACR50: American College of Rheumatology 50% response criteria, based on count of swollen and tender joints (out of 28 joints), blood test measures of inflammation (such as CRP) and the physician and patient's own assessments of disease activity, pain and physical function. BID = twice daily, CRP = C-reactive protein, DMARD = Disease-modifying anti-rheumatic drug, PO = orally, QD = once a day.
Measured: 24 weeks
Proportion of Patients Achieving ACR70, Comparison Between Fostamatinib and Placebo at Week 24
ACR70: American College of Rheumatology 70% response criteria, based on count of swollen and tender joints (out of 28 joints), blood test measures of inflammation (such as CRP) and the physician and patient's own assessments of disease activity, pain and physical function. BID = twice daily, CRP = C-reactive protein, DMARD = Disease-modifying anti-rheumatic drug, PO = orally, QD = once a day.
Measured: 24 weeks
ACRn - Comparison Between Fostamatinib and Placebo at Week 24
ACRn: American College of Rheumatology index of RA improvement, based on smallest percentage improvement in the count of swollen joints (out of 28 joints), count of tender joints (out of 28 joints), or in blood test measures of inflammation (such as CRP) or the physician or patient's own assessments of disease activity, pain and physical function. Scores are reported as a percentage improvement on a scale of -100 to +100, with larger values representing a better clinical outcome. BID = twice daily, CI = confidence interval, CRP = C-reactive protein, DMARD = Disease-modifying anti-rheumatic drug, PO = orally, QD = once a day. Mean refers to change at Week 24.
Measured: Baseline and 24 weeks
Proportion of Patients Achieving DAS28-CRP <2.6 at Week 12, Comparison Between Fostamatinib and Placebo
DAS28-CRP: Disease Activity Score based on a count of swollen and tender joints (out of 28 joints), blood test measures of inflammation (CRP) and the patient's own assessment. Scores can take any positive value with a lower value indicating a better clinical condition. A DAS28-CRP score of <2.6 is indicative of remission of RA symptoms. BID = twice daily, CRP = C-reactive protein, DMARD = Disease-modifying anti-rheumatic drug, OR = odds ratio, PO = orally, QD = once a day.
Measured: 12 weeks
Proportion of Patients Achieving DAS28-CRP <2.6 at Week 24, Comparison Between Fostamatinib and Placebo
DAS28-CRP: Disease Activity Score based on a count of swollen and tender joints (out of 28 joints), blood test measures of inflammation (CRP) and the patient's own assessment. Scores can take any positive value with a lower value indicating a better clinical condition. A DAS28-CRP score of <2.6 is indicative of remission of RA symptoms. BID = twice daily, CRP = C-reactive protein, DMARD = Disease-modifying anti-rheumatic drug, OR=odds ratio, PO = orally, QD=once a day.
Measured: 24 weeks
Proportion of Patients Achieving DAS28 EULAR Response at Week 24
Change in DAS28 was derived for each post baseline scheduled assessment and categorised using the European League Against Rheumatism (EULAR) response criteria. BID = twice daily, DAS28 = Disease Activity Score based on a 28-joint count, DMARD = disease-modifying anti-rheumatic drug, OR=odds ratio, PO = orally, QD = once a day.
Measured: 24 weeks
HAQ-DI Response - Comparison of the Change(>=0.22) From Baseline Between Fostamatinib and Placebo at Week 24
HAQ-DI: Health Assessment Questionnaire - Disability Index, a measure of physical function. The HAQ-DI score is then calculated by summing the category scores from 8 sub-categories (ie, scores for patient ability in dressing and grooming, rising, eating, walking, hygiene, reach, grip and common daily activities) and dividing by the number of categories completed. The HAQ-DI score takes values between 0 and 3, with a higher score indicating greater disability. The HAQ-DI response is a reduction from baseline in HAQ-DI score greater than or equal to the minimally important difference (0.22). BID = twice daily, DMARD = disease-modifying anti-rheumatic drug, OR = odds ratio, PO = orally, QD = once a day.
Measured: Baseline and 24 weeks
Change From Baseline to Week 24 in mTSS, Comparison Between Fostamatinib and Placebo
mTSS: modified total sharp score, a measure of structural progression based upon X-rays. Hand and foot joints are scored for erosions and joint space narrowing and the results summed to give a value between 0 and 448. A higher value represents more serious progression of the disease. After disregarding ineligible records, patients with 2 or more non-missing values have had missing data imputed via linear extrapolation/interpolation methods. Patients with only 1 result were excluded from the analysis. ANCOVA = analysis of covariance, BID = twice daily, IP = investigational product, QD = once a day.
Measured: Baseline and 24 weeks
SF-36 - Comparison of the Change in PCS From Baseline Between Fostamatinib and Placebo at Week 24
SF-36: 36-item Short Form Health Survey, a measure of health related quality of life. Scores for 8 sub-domains (Physical Functioning, Role-Physical, Bodily Pain, General Health, Vitality, Social Function, Role-Emotional and Mental Health) are derived and normalised to a scale of 0-100. Physical and mental component scores (PCS and MCS) are derived by multiplying each of these 8 scores by a constant, summing them and standardising against a population with mean of 50+/- 10. Higher scores represent a better quality of life. Mean changes from baseline score are presented as increases from baseline (defined as post-baseline minus baseline); larger changes indicate a better clinical condition. ANCOVA = analysis of covariance, BID = twice daily, DMARD = disease modifying antirheumatic drugs, PO = orally, QD = once a day.
Measured: Baseline and 24 weeks
SF-36 - Comparison of the Change in MCS From Baseline Between Fostamatinib and Placebo at Week 24
SF-36: 36-item Short Form Health Survey, a measure of health related quality of life. Scores for 8 sub-domains (Physical Functioning, Role-Physical, Bodily Pain, General Health, Vitality, Social Function, Role-Emotional and Mental Health) are derived and normalised to a scale of 0-100. Physical and mental component scores (PCS and MCS) are derived by multiplying each of these 8 scores by a constant, summing them and standardising against a population with mean of 50+/- 10. Higher scores represent a better quality of life. Mean changes from baseline score are presented as increases from baseline (defined as post-baseline minus baseline); larger changes indicate a better clinical condition. ANCOVA = analysis of covariance, BID = twice daily, DMARD = disease modifying antirheumatic drugs, PO = orally, QD = once a day.
Measured: Baseline and 24 weeks
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted9 Sep 2010 (estimated)
- Study startSep 2010
- Primary completionMar 2013
- Study completionMar 2013
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Posted resultsParticipant flow, outcome measures and adverse events reported by the sponsor.
- Other trials for Rheumatoid ArthritisStudies of the same condition, open and under way.
- More trials run by AstraZenecaThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 3
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Quadruple blind
- Who is masked
- Participant, Care provider, Investigator, Outcomes assessor
- Enrolment
- 913 participants (actual)
Sponsor and investigators
- Lead sponsor
- AstraZeneca
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
- Investigators
- Neil MacKillop, MD PhD, Study director, AstraZeneca
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT01197534
- Sponsor's protocol ID
- D4300C00002
- Other IDs
- 2010-020744-35
- Acronym
- OSKIRA - 2
- Status last verified
- Mar 2014
- First submitted
- 8 Sep 2010
- Last updated
- 17 Apr 2014
- Results posted
- Yes, on ClinicalTrials.gov
- Data monitoring committee
- Yes
Study at a glance
From the registry record, last updated by the sponsor on 17 Apr 2014. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- (OSKIRA-2): A Phase III, Multi-centre, Randomised, Double-Blind, Placebo-Controlled, Parallel Group Study of Two Dosing Regimens of Fostamatinib Disodium in Rheumatoid Arthritis Patients With an Inadequate Response to DMARDs
- ClinicalTrials.gov ID
- NCT01197534
- Acronym / sponsor ID
- OSKIRA - 2 / D4300C00002
- Conditions
- Rheumatoid Arthritis
- Keywords
- Rheumatoid Arthritis
- Phase
- Phase 3
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 913 participants (actual)
- Lead sponsor
- AstraZenecaIndustry (pharma, biotech, devices)
- Study start
- Sep 2010
- Primary completion
- Mar 2013 (actual)
- Study completion
- Mar 2013 (actual)
- First posted
- 9 Sep 2010 (estimated)
- Results
- Posted 17 Apr 2014
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The purpose of the study is to evaluate the effectiveness of two dosing regimens of fostamatinib compared to placebo, in patients with rheumatoid arthritis (RA) who are taking disease modifying anti-rheumatic drug (DMARD) but not responding. The study will last for 1 year.
Detailed description
Sub-study:
Full title: Optional Genetic Research
Date: 18 June 2010
Version: 1
Objectives: To collect and store, with appropriate consent ,DNA samples for future exploratory research into genes/genetic variation that may influence response (ie, absorption, distribution, metabolism and excretion, safety, tolerability and efficacy) to fostamatinib disodium and/or methotrexate; and/or susceptibility to, progression of and prognosis of RA
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Quadruple blind (participant, care provider, investigator, outcomes assessor)
- Number of arms
- 3
| Arm | Type | Receives |
|---|---|---|
| Dosing Regimen A | Experimental | Drug: fostamatinibOral Treatment |
| Dosing Regimen B | Experimental | Drug: fostamatinibOral Treatment |
| Dosing Regimen C | Placebo comparator | Drug: placebo, fostamatinibOral Treatment |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (4 listed)
- Active rheumatoid arthritis (RA) diagnosed after the age of 16
- Treatment with one the following disease modifying anti-rheumatic drug: methotrexate, sulfasalazine, hydroxychloroquine or chloroquine
- 4 or more swollen joints and 4 or more tender/painful joints (from 28 joint count)and either Erythrocyte Sedimentation Rate (ESR) blood result of 28mm/h or more, or C-Reactive Protein (CRP) blood result of 10mg/L or more
- At least one of the following: documented history of positive rheumatoid factor (blood test), current presence of rheumatoid factor (blood test), radiographic erosion within 12 months prior to study enrolment, presence of serum anti-cyclic citrullinated peptide antibodies (blood test)
Key exclusion criteria (9 listed)
- Females who are pregnant or breast feeding
- Poorly controlled hypertension
- Liver disease or significant liver function test abnormalities
- Certain inflammatory conditions (other than rheumatoid arthritis), connective tissue diseases or chronic pain disorders
- Recent or significant cardiovascular disease
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| fostamatinibfostamatinib 100 mg twice daily | Drug | Dosing Regimen A |
| fostamatinibfostamatinib 100 mg twice daily/ 150 mg once daily | Drug | Dosing Regimen B |
| placebo, fostamatinibPlacebo for 24 weeks followed by fostamatinib 100 mg twice daily. | Drug | Dosing Regimen C |
Primary outcome
Proportion of Patients With ACR20 at Week 24, Comparison Between Fostamatinib and Placebo
Time frame: 24 weeks
ACR20: American College of Rheumatology 20% response criteria, based on count of swollen and tender joints (out of 28 joints), blood test measures of inflammation (such as CRP) and the physician and patient's own assessments of disease activity, pain and physical function. BID = twice daily, CRP = C-reactive protein, DMARD = disease-modifying anti-rheumatic drug, PO = orally, QD = once a day.
11 secondary outcomes
Proportion of Patients Achieving ACR20, Comparison Between Fostamatinib and Placebo at Week 1
Time frame: 1 week
Proportion of Patients Achieving ACR50, Comparison Between Fostamatinib and Placebo at Week 24
Time frame: 24 weeks
Proportion of Patients Achieving ACR70, Comparison Between Fostamatinib and Placebo at Week 24
Time frame: 24 weeks
ACRn - Comparison Between Fostamatinib and Placebo at Week 24
Time frame: Baseline and 24 weeks
Proportion of Patients Achieving DAS28-CRP <2.6 at Week 12, Comparison Between Fostamatinib and Placebo
Time frame: 12 weeks
Proportion of Patients Achieving DAS28-CRP <2.6 at Week 24, Comparison Between Fostamatinib and Placebo
Time frame: 24 weeks
Proportion of Patients Achieving DAS28 EULAR Response at Week 24
Time frame: 24 weeks
HAQ-DI Response - Comparison of the Change(>=0.22) From Baseline Between Fostamatinib and Placebo at Week 24
Time frame: Baseline and 24 weeks
Change From Baseline to Week 24 in mTSS, Comparison Between Fostamatinib and Placebo
Time frame: Baseline and 24 weeks
SF-36 - Comparison of the Change in PCS From Baseline Between Fostamatinib and Placebo at Week 24
Time frame: Baseline and 24 weeks
SF-36 - Comparison of the Change in MCS From Baseline Between Fostamatinib and Placebo at Week 24
Time frame: Baseline and 24 weeks
Results and safety
Loading the posted results from ClinicalTrials.gov…
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 17 Apr 2014.
- Posted resultsParticipant flow, baseline, all outcome measures and adverse events.
- Related InfoLink provided by the sponsor.
- Related InfoLink provided by the sponsor.
- Related InfoLink provided by the sponsor.
Related trials for Rheumatoid Arthritis
RecruitingPhase 2
Study of PTC844 in Participants With Active Rheumatoid Arthritis
Rheumatoid Arthritis
Not yet recruitingPhase 1
An Ascending Dose Study of DKB903 in Participants With Rheumatoid Arthritis (RA) and Participants With Systemic Lupus Erythematosus (SLE)
Rheumatoid Arthritis and Systemic Lupus Erythematosus
Not yet recruitingPhase 1
R-2487 in Patients With Sjogren's Syndrome (SjD)
Sjogren's Syndrome, Sjögren
RecruitingPhase 1
A Trial in Healthy Adult Participants and Adults With Autoimmune Diseases to Test How HBM7020 is Tolerated and How it Behaves in the Body
Rheumatoid Arthritis, Systemic Lupus Erythematosus
Active, not recruitingPhase 2
A Study Evaluating the Safety and Efficacy of Inhaled AP01 in Participants With Progressive Pulmonary Fibrosis
Pulmonary Fibrosis, Progressive Pulmonary Fibrosis
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Neil MacKillop, MD PhD study director
AstraZeneca
149 sites in 16 countries: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 3 study testing fostamatinib in people with Rheumatoid Arthritis, run by AstraZeneca at 149 sites in 16 countries.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 9 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 17 Apr 2014. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 149 sites in United States, Canada, Czechia, India, United Kingdom and 11 more countries. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 3 studies compare the treatment with the current standard treatment or a placebo in a large group, to confirm how well it works and watch for side effects.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
Yes. Results are posted in the registry (first posted 17 Apr 2014). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Proportion of Patients With ACR20 at Week 24, Comparison Between Fostamatinib and Placebo (time frame: 24 weeks). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 17 Apr 2014.